In-vitro maturation of human oocytes: before or after vitrification?

Fasano, Giovanna; Demeestere, Isabelle; Englert, Yvon

doi:10.1007/s10815-012-9751-9

Cited by 65 publications

(44 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, Fasano et al [72] showed that IVM procedure is more efficient when it is performed before oocyte vitrification. In this study, a total of 184 immature oocytes were randomly divided into two different groups: 100 were vitrified at MII-stage after IVM and 84 were immediately vitrified at GV-stage and in vitro matured after warming.…”

Section: Clinical Application Of Immature Oocyte Cryopreservationmentioning

confidence: 93%

The current challenges to efficient immature oocyte cryopreservation

Brambillasca

Guglielmo

Coticchio

et al. 2013

J Assist Reprod Genet

View full text Add to dashboard Cite

Oocyte cryopreservation represents an important tool for assisted reproductive technology. It offers the opportunity to preserve fertility in women at risk of loss of the ovarian function for various pathologies. It also represents a treatment alternative for couples that cannot benefit from embryo cryopreservation because of moral, religious, or legal constrains. On the other hand, in vitro oocyte maturation has a range of applications. It can be applied in patients with a contraindication to ovarian stimulation to prevent ovarian hyperstimulation syndrome or to eliminate the risk of stimulation of hormone-sensitive tumours in cancer patients. However, while mature oocyte cryopreservation has found widespread application and oocyte in vitro maturation has a place for the treatment of specific clinical conditions, data on the efficiency of freezing of immature or in vitro matured oocytes are poorer. In this review we will focus on the combination of oocyte in vitro maturation with oocyte cryopreservation with particular emphasis on the biological implications of the cryopreservation of immature or in vitro matured oocytes. The two cryopreservation approaches, slow freezing and vitrification, will be discussed in relation to possible cryodamage occurring to subcellular structures of the oocyte and the functional interaction between oocyte and cumulus cells.

show abstract

Section: Clinical Application Of Immature Oocyte Cryopreservationmentioning

confidence: 93%

The current challenges to efficient immature oocyte cryopreservation

Brambillasca

Guglielmo

Coticchio

et al. 2013

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

“…Unless noted otherwise, all studies discussed herein are in human. Table 2 summarizes the ranges of values obtained from a total of 23 studies that cryopreserved human oocytes at the GV stage, 14 and 12 of which used slow-freezing or vitrification protocols, respectively (Mandelbaum et al, 1988;Toth et al, 1994a;Toth et al, 1994b;Baka et al, 1995;Son et al, 1996;Park et al, 1997;Chung et al, 2000;Goud et al, 2000;Wu et al, 2001;Boiso et al, 2002;Chen et al, 2004;Fuchinoue et al, 2004;Isachenko et al, 2006;Cao et al, 2009;Fasano et al, 2010;Al-Khtib et al, 2011;Combelles et al, 2011;Criado et al, 2011;Liu et al, 2011;Versieren et al, 2011;Zhang et al, 2011;Fasano et al, 2012;Wang et al, 2012). Seventy percent (16/23) of studies evaluated the in vitro developmental competence of cryopreserved GV oocytes based on fertilization, cleavage, and in some instances even blastocyst formation.…”

Section: Advantages and Drawbacks Of Cryopreserving Immature Oocytes mentioning

confidence: 99%

“…design (Fasano et al, 2012;Wang et al, 2012). However in the Fasano et al, (2012) study, GV and M-I failed to mature oocytes were both included, and it is not clear that GV oocytes from a single patient were randomly allocated to either treatment groups (versus a random allocation of GV and M-I oocytes together).…”

Section: Side-by-side Comparisons Of the Cryopreservation Of Immaturementioning

confidence: 99%

“…However in the Fasano et al, (2012) study, GV and M-I failed to mature oocytes were both included, and it is not clear that GV oocytes from a single patient were randomly allocated to either treatment groups (versus a random allocation of GV and M-I oocytes together). Five and three studies used a slow-freezing and vitrification protocol, respectively.…”

Section: Side-by-side Comparisons Of the Cryopreservation Of Immaturementioning

confidence: 99%

“…Three of these eight studies did not test developmental competence in vitro, but rather focused on an assessment of spindle and chromosome organization (not all of which relied on a powerful and most reliable three-dimensional imaging with confocal laser-scanning microscopy) (Table 3). When assessing results across studies, trends can be gathered (Table 3); one rather small study (n=52 and 68 GVs in each treatment arm) that gave unusually low results (even with maturation prior to vitrification) is excluded from the following discussion (Fasano et al, 2012). It is apparent that most studies report comparable survival rates, with maturation systematically compromised when cryopreserving at the GV stage (30-56% versus 70-85% when cryopreserving at the GV versus M-II stage).…”

Section: Side-by-side Comparisons Of the Cryopreservation Of Immaturementioning

confidence: 99%

See 2 more Smart Citations

The use of immature oocytes in the fertility preservation of cancer patients: current promises and challenges

Combelles¹,

Chateau²

2012

Int. J. Dev. Biol.

View full text Add to dashboard Cite

Improved oncological treatments permit increased survival rates, although cancer patients remain at risk of losing ovarian function. An attractive option for fertility preservation includes the use of immature oocytes, a strategy which can occur on a rapid timeline and without hormonal stimulation. As a result, cancer therapy can proceed promptly even in patients with hormone-sensitive tumors. Following retrieval, immature oocytes can be cryopreserved at either the immature germinal vesicle or the mature metaphase-II stage, i.e. either before or after in vitro maturation (IVM). We present a critical review of previous human studies on the cryopreservation of immature oocytes. Evaluations include in vitro developmental competence upon thawing/warming, or organization of the spindle and chromosomes. Reported successes vary, perhaps in relation to the source of the oocytes and protocols for cryopreservation and IVM. Weaknesses exist with the experimental designs implemented to date, so caution must be exercised before considering the use of immature oocytes to be a safe and reliable practice in the fertility preservation of cancer patients. To date, results indicate that with current protocols, it may be best to cryopreserve immature oocytes after IVM at the metaphase-II stage. Nonetheless, efficacy remains very low. Future efforts should tailor and optimize not only cryopreservation, but also IVM protocols for use in either germinal vesicle or metaphase-II oocytes, together with a comprehensive assessment of oocyte function and developmental competence to term. Despite current challenges, the burgeoning field of immature oocyte cryopreservation constitutes a promising option for cancer patients with impaired ovarian function. KEY WORDS: immature oocyte, fertility preservation, cryopreservation, cancer, in vitro maturation Why target immature oocytes in cancer patients?In the last few decades, the incidence of cancer and the likelihood of survival have risen across the globe. A little over 1 in 3 women in North America are diagnosed with cancer every year. This constitutes an overwhelming number of young women of reproductive age undergoing chemotherapy, radiotherapy, and other oncologic treatments; an estimated 9% of cancer survivors are 20-39 years old in the United States. Invasive cancers are treated aggressively through chemotherapy, radiotherapy and surgeries to remove cancerous cells and masses. Unfortunately such treatments create irreversible damage to the gonads and possible sterility (reviewed by Anchan and Ginsburg, 2010). Depending on the type and dose, oncological therapies may result in damage and/or loss of not only germ cells but also the supporting somatic compartments of the ovarian follicle. Due to the women's finite number of oocytes and the irreplaceable nature of the pool Int. J. Dev. Biol. 56: 919-929 (2012)

show abstract

In vitro maturation of human immature oocytes for fertility preservation and research material

Shirasawa

Terada

2017

Reprod Medicine & Biology

View full text Add to dashboard Cite

AimIn recent years, the importance of fertility preservation (FP) has increased. In vitro maturation (IVM), an important technique in FP, has started to be used in the clinic, but controversies persist regarding this technique. Here, a survey of IVM for FP is provided.MethodsBased on a literature review, the applications of FP, methods of FP, IVM of oocytes that had been collected in vivo and ex vivo, maturation of oocytes after IVM for FP, cryopreservation of oocytes for FP, explanation of the procedures to patients, and recent research on FP using IVM were investigated.ResultsAlthough IVM for FP remains controversial, the application of FP is expected to expand. Depending on the age and disease status of the patient, various methods of oocyte collection and ovarian stimulation, as well as various needle types and aspiration pressures, have been reported. The maturation rate of IVM in FP ranges widely and requires optimization in the future. In regard to cryopreservation for matured oocytes, the vitrification method is currently recommended.ConclusionRegarding FP for patients with cancer, the treatment of cancer is prioritized; thus, the time and use of medicines are often constrained. As several key points regarding IVM remain unclear, well‐designed and specific counseling for patients is necessary.

show abstract

In-vitro maturation of human oocytes: before or after vitrification?

Cited by 65 publications

References 36 publications

The current challenges to efficient immature oocyte cryopreservation

The current challenges to efficient immature oocyte cryopreservation

The use of immature oocytes in the fertility preservation of cancer patients: current promises and challenges

In vitro maturation of human immature oocytes for fertility preservation and research material

Contact Info

Product

Resources

About